What is Annoroad?
Annoroad operates as a premier medical genomics center, distinguished by its status as a national high-tech enterprise and a key participant in China's precision medicine initiatives. The company maintains a vertically integrated business model, encompassing the development of high-throughput benchtop sequencers like the NextSeq 550AR and the SolarGenomics cloud platform. By leveraging a sophisticated talent pool and advanced high-performance computing infrastructure, Annoroad provides critical services that bridge the gap between life science research and clinical application. Its market influence is further solidified by its inclusion in the Beijing Biopharmaceutical Industry Leap-forward Development Program, positioning it as a critical infrastructure provider for the future of genetic engineering in Asia.
How much funding has Annoroad raised?
Annoroad has raised a total of $100M across 1 funding round:
Series C
$100M
Series C (2017): $100M with participation from SBCVC, SAIF Partners, ShenZhen GTJA Investment Group, and Ping An Ventures
Key Investors in Annoroad
SBCVC
A leading venture capital and private equity firm managing both USD and RMB funds, focusing on high-growth companies in healthcare, TMT, and advanced manufacturing.
SAIF Partners
A prominent private equity firm providing growth capital to companies in China, with a specialized focus on healthcare, internet+, and new materials.
ShenZhen GTJA Investment Group
An investment group dedicated to the healthcare industry, specializing in pharmaceuticals, medical apparatus, and comprehensive medical services.
What's next for Annoroad?
With the successful closure of this major strategic investment, Annoroad is well-positioned to accelerate its R&D initiatives and expand its footprint in the global genomics market. The capital will likely be deployed to enhance its proprietary sequencing technologies and strengthen its Bio-IT industrial service capabilities. As the company continues to integrate its upstream and downstream operations, it remains focused on maintaining its competitive edge in the high-growth precision medicine sector, potentially targeting further international expansion and the commercialization of its next-generation diagnostic tools.
See full Annoroad company page
